Citations

Clear

4847 citation(s) found for "Tu, Eric".

Brain metal concentrations in chronic liver failure patients with pallidal T1 MRI hyperintensity
Klos, Kevin J., Ahlskog, J. Eric , Kumar, Neeraj , Cambern, Sarah J, Butz, James J. , Mf, Burritt, Fealey, Robert D., Cowl, Clayton T. , Parisi, J. E., Josephs, Keith A.

Mayo Clinic

Neurology | December 13, 2006 | Volume: 67 | Issue: 11 | Pages: 1984-1989

10.1212/01.wnl.0000247037.37807.76 | PMID 17159105 Get It

A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Gojo, Ivana , Feldman, Eric J. , Greer, Jacqueline M., Bruzek, Laura M., Morris, Lawrence E. , Park, Youn, Adjei, Alex A. , Greenberg, Peter L. , Wright, John J., Karp, Judith E. , Lancet, Jeffrey E. , Gotlib, Jason , Liesveld, Jane L. , Kaufmann, Scott H. , Garrett‐Mayer, Elizabeth , Wright, John J.

Mayo Clinic

Blood | November 3, 2006 | Volume: 109 | Issue: 4 | Pages: 1387-1394

10.1182/blood-2006-04-014357 | PMID 17082323 Get It

AbstractOutcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a majority of patients had antecedent myelodysplastic syndrome. Complete remission (CR) was achieved in 22 patients (14%); partial remission or hematologic improvement occurred in 15 patients, for an overall response rate of 23%. The median duration of CR was 7.3 months and the median survival of complete responders was 18 months. Adverse karyotype, age 75 years or older, and poor performance status correlated negatively with survival. Early death in the absence of progressive disease was rare, and drug-related nonhematologic serious adverse events were observed in 74 patients (47%). Inhibition of farnesylation of the surrogate protein HDJ-2 occurred in the large majority of marrow samples tested. Baseline levels of phosphorylated mitogen-activated protein kinase and AKT did not correlate with clinical response. Tipifarnib is active and well tolerated in older adults with poor-risk AML and may impart a survival advantage in those patients who experience a clinical response.
Gene expression profiles in anatomically and functionally distinct regions of the normal aged human brain
Liang, Winnie S. , Dunckley, Travis , Beach, Thomas G. , Grover, Andrew, Mastroeni, Diego , Walker, Douglas G. , Caselli, Richard J. , Kukull, Walter A. , McKeel, Daniel W., Morris, John C. , Hulette, Christine, Schmechel, Donald E., Alexander, Gene E. , Reiman, Eric M. , Rogers, Joseph, Stephan, Dietrich A. , Morris, John C

Mayo Clinic

Physiological Genomics | October 31, 2006 | Volume: 28 | Issue: 3 | Pages: 311-322

10.1152/physiolgenomics.00208.2006 | PMID 17077275 Get It

In this article, we have characterized and compared gene expression profiles from laser capture microdissected neurons in six functionally and anatomically distinct regions from clinically and histopathologically normal aged human brains. These regions, which are also known to be differentially vulnerable to the histopathological and metabolic features of Alzheimer’s disease (AD), include the entorhinal cortex and hippocampus (limbic and paralimbic areas vulnerable to early neurofibrillary tangle pathology in AD), posterior cingulate cortex (a paralimbic area vulnerable to early metabolic abnormalities in AD), temporal and prefrontal cortex (unimodal and heteromodal sensory association areas vulnerable to early neuritic plaque pathology in AD), and primary visual cortex (a primary sensory area relatively spared in early AD). These neuronal profiles will provide valuable reference information for future studies of the brain, in normal aging, AD and other neurological and psychiatric disorders.
Implantable Doppler flow system: Experience with 24 microvascular free‐flap operations
Pryor, Shepherd G., Moore, Eric J. , Kasperbauer, Jan L.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 28, 2006 | Volume: 135 | Issue: 5 | Pages: 714-718

10.1016/j.otohns.2006.05.006 | PMID 17071300 Get It

ObjectiveMicrovascular reconstruction requires postoperative monitoring to prevent vascular occlusion and flap failure. These methods require skilled personnel and can delay diagnosis and treatment of threatened flap failures. The Cook‐Swartz implantable Doppler flow system provides continual feedback on vascular pedicle status, which in turn provides rapid assessment of minute‐to‐minute changes in flap vasculature that may allow intervention before total vascular occlusion and expeditious reexploration for threatened flap failure, possibly improving flap salvage.Study Design and SettingCharts of 24 patients with microvascular free‐flap reconstruction and implantation of Doppler flow system at Mayo Clinic Rochester were retrospectively reviewed. Surgical technique and flap outcomes were evaluated.ResultsMicrovascular reconstruction and implantation of Doppler flow system were successful in all patients. Complications were minimal, and postoperative monitoring system facilitated rapid reexploration when necessary. Flap viability was 96%.ConclusionDoppler flow system is reliable for monitoring minute‐to‐minute changes in microvascular flap vascular status postoperatively, and allows rapid recognition of complications and facilitating reexploration. This is a valuable, easily mastered tool for microvascular reconstructive surgery.SignificanceMay alter postoperative monitoring techniques of microvascular surgeons.
A Systematic Method for Selection of Promising Serum Protein Biomarkers to Improve Prostate Cancer (PCa1) Detection
Finlay, Judith A., Klee, Eric W. , McDonald, Cari, Attewell, John R., Hebrink, Deanne, Dyer, Roy B. , Vasmatzis, George , Li, Thomas M, Beechem, Joseph , Klee, George G., Love, Brad

Mayo Clinic

Clinical Chemistry | October 26, 2006 | Volume: 52 | Issue: 11 | Pages: 2159-2162

10.1373/clinchem.2006.072959 | PMID 18061988 Get It

Bioinformatics Methods for Prioritizing Serum Biomarker Candidates
Klee, Eric W. , Finlay, Judith A., McDonald, Cari, Attewell, John R., Hebrink, Deanne, Dyer, Roy B. , Vasmatzis, George , Li, Thomas M, Beechem, Joseph , Klee, George G., Love, Brad

Mayo Clinic

Clinical Chemistry | October 26, 2006 | Volume: 52 | Issue: 11 | Pages: 2162-2164

10.1373/clinchem.2006.072868 | PMID 18061989 Get It

Chorea as a manifestation of spontaneous CSF leak
Mokri, Bahram, Ahlskog, J. Eric , Luetmer, Patrick H.

Mayo Clinic

Neurology | October 24, 2006 | Volume: 67 | Issue: 8 | Pages: 1490-1491

10.1212/01.wnl.0000240059.96502.bf | PMID 17060583 Get It

Common Kibra Alleles Are Associated with Human Memory Performance
Papassotiropoulos, Andreas , Stephan, Dietrich , Huentelman, Matthew J. , Craig, David W. , Pearson, John V. , Huynh, Kim-Dung, Brunner, Fabienne, Corneveaux, Jason J., Osborne, David, Wollmer, M. Axel, Aerni, Amanda , Coluccia, Daniel , Hänggi, Jürgen , Mondadori, Christian R.A., Buchmann, Andreas , Reiman, Eric M. , Caselli, Richard J. , Quervain, Dominique J.‐F. de , Hoerndli, Frédéric J. , Henke, Katharina

Mayo Clinic

Science | October 19, 2006 | Volume: 314 | Issue: 5798 | Pages: 475-478

10.1126/science.1129837 | PMID 17053149 Get It

Human memory is a polygenic trait. We performed a genome-wide screen to identify memory-related gene variants. A genomic locus encoding the brain protein KIBRA was significantly associated with memory performance in three independent, cognitively normal cohorts from Switzerland and the United States. Gene expression studies showed that KIBRA was expressed in memory-related brain structures. Functional magnetic resonance imaging detected KIBRA allele–dependent differences in hippocampal activations during memory retrieval. Evidence from these experiments suggests a role for KIBRA in human memory.
A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer
Hidalgo, Manuel , Buckner, Jan C. , Erlichman, Charles , Pollack, Marilyn S., Boni, Joseph , Dukart, Gary, Marshall, Bonnie, Speicher, Lisa A., Rowinsky, Eric K. , Moore, Laurence

Mayo Clinic

Clinical Cancer Research | October 4, 2006 | Volume: 12 | Issue: 19 | Pages: 5755-5763

10.1158/1078-0432.ccr-06-0118 | PMID 17020981 Get It

Abstract Purpose: Patients with advanced cancer received temsirolimus (Torisel, CCI-779), a novel inhibitor of mammalian target of rapamycin, i.v. once daily for 5 days every 2 weeks to determine the maximum tolerated dose, toxicity profile, pharmacokinetics, and preliminary antitumor efficacy. Experimental Design: Doses were escalated in successive cohorts of patients using a conventional phase I clinical trial design. Samples of whole blood and plasma were collected to determine the pharmacokinetics of temsirolimus and sirolimus, its principal metabolite. Results: Sixty-three patients were treated with temsirolimus (0.75-24 mg/m2/d). The most common drug-related toxicities were asthenia, mucositis, nausea, and cutaneous toxicity. The maximum tolerated dose was 15 mg/m2/d for patients with extensive prior treatment because, in the 19 mg/m2/d cohort, two patients had dose-limiting toxicities (one with grade 3 vomiting, diarrhea, and asthenia and one with elevated transaminases) and three patients required dose reductions. For minimally pretreated patients, in the 24 mg/m2/d cohort, one patient developed a dose-limiting toxicity of grade 3 stomatitis and two patients required dose reductions, establishing 19 mg/m2/d as the maximum acceptable dose. Immunologic studies did not show any consistent trend toward immunosuppression. Temsirolimus exposure increased with dose in a less than proportional manner. Terminal half-life was 13 to 25 hours. Sirolimus-to-temsirolimus exposure ratios were 0.6 to 1.8. A patient with non–small cell lung cancer achieved a confirmed partial response, which lasted for 12.7 months. Three patients had unconfirmed partial responses; two patients had stable disease for ≥24 weeks. Conclusion: Temsirolimus was generally well tolerated on this intermittent schedule. Encouraging preliminary antitumor activity was observed.
An Essential Role for LEDGF/p75 in HIV Integration
Llano, Manuel , Saenz, Dyana T. , Meehan, Anne M. , Wongthida, Phonphimon , Peretz, Mary, Teo, Wulin , Poeschla, Eric M. , Walker, William H.

Mayo Clinic

Science | September 8, 2006 | Volume: 314 | Issue: 5798 | Pages: 461-464

10.1126/science.1132319 | PMID 16959972 Get It

Chromosomal integration enables human immunodeficiency virus (HIV) to establish a permanent reservoir that can be therapeutically suppressed but not eradicated. Participation of cellular proteins in this obligate replication step is poorly understood. We used intensified RNA interference and dominant-negative protein approaches to show that the cellular transcriptional coactivator lens epithelium–derived growth factor (LEDGF)/p75 (p75) is an essential HIV integration cofactor. The mechanism requires both linkages of a molecular tether that p75 forms between integrase and chromatin. Fractionally minute levels of endogenous p75 are sufficient to enable integration, showing that cellular factors that engage HIV after entry may elude identification in less intensive knockdowns. Perturbing the p75-integrase interaction may have therapeutic potential.